(Q41002117)

English

A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer

scientific article published on 4 January 2016

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

phase II clinical trial

0 references

author name string

Masanori Noguchi

1

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Fukuko Moriya

2

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Noriko Koga

3

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Satoko Matsueda

4

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Tetsuro Sasada

5

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Akira Yamada

6

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Tatsuyuki Kakuma

7

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Kyogo Itoh

8

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

publication date

4 January 2016

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

65

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

151-160

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1781-6

21 January 2018

Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1781-6

21 January 2018

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1781-6

21 January 2018

Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1781-6

21 January 2018

Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1781-6

21 January 2018

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1781-6

21 January 2018

Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1781-6

21 January 2018

Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1781-6

21 January 2018

Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1781-6

21 January 2018

A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1781-6

21 January 2018

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1781-6

21 January 2018

Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1781-6

21 January 2018

Metronomic chemotherapy: changing the paradigm that more is better

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1781-6

21 January 2018

Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer: review of the literature.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1781-6

21 January 2018

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1781-6

21 January 2018

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1781-6

21 January 2018

The terminology issue for myeloid-derived suppressor cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1781-6

21 January 2018

Cyclophosphamide induces the development of early myeloid cells suppressing tumor cell growth by a nitric oxide-dependent mechanism.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1781-6

21 January 2018

Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1781-6

21 January 2018

CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1781-6

21 January 2018

Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing Host

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1781-6

21 January 2018

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1781-6

21 January 2018

Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1781-6

21 January 2018

Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1781-6

21 January 2018

Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1781-6

21 January 2018

Identifiers

10.1007/S00262-015-1781-6

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41002117&oldid=2204174569"